Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Barr Laboratory BRL -- Ignore unavailable to you. Want to Upgrade?

To: E. Graphs who wrote (173)	6/25/1999 3:44:00 PM
From: E. Graphs	Read Replies (1) \| Respond to of 207

Barr gets U.S. marketing approval for cefadroxil POMONA, N.Y., June 23 (Reuters) - >>Barr Laboratories Inc. (NYSE:BRL - news), the sixth largest independent U.S. generic drug maker, said Wednesday it won U.S. marketing approval for cefadroxil in 500 milligram capsules for the treatment of urinary tract infections. Cefadroxil is the generic version of Bristol-Myers Squibb Co's (NYSE:BMY - news) Durice drug, and Barr said it will begin shipping its new product immediately. Barr, the third company to enter the 500 mg market for cefadroxil, also said it has entered into a joint venture partnership with privately-held Ranbaxy Pharmaceuticals Inc., which makes cefadroxil in 1 gram tablets. Under the partnership, the two companies will co-market their products. The 500 mg capsule and 1 gram tablet strengths have a combined market value of about $61 million, Barr said.<<